RECIST V1.1 How? - Why? - Why not? overview context shortcomings and success: RCC, HIF2a скачать в хорошем качестве

RECIST V1.1 How? - Why? - Why not? overview context shortcomings and success: RCC, HIF2a

The teaching video explains the response criteria RECIST Version1.1 for the new comer in clinical development of cancer drugs. It shows where the find the publication, why it was necessary, and successful. It also shows the limitations and errors you need to know, so you use the guideline appropriate. As example for RECIST success, a publication is discussed that used RECIST and brought a drug to approval, kidney cancer is explained. Cancer | Oncology | drug development | clinical development | efficacy | response | CR | PR | SD | PD | ORR | kidney cancer | HIF-2a | tumor | FDA |approval | phase 2 The video is part of a teaching series aiming to help our young colleagues in drug development get on their feet faster. There are others: • KM curve – What is that? The basics    • Kaplan Meier Curve - What is that ? the Ba...   • PFS progression free survival explained    • PFS progression free survival explained   • Reading KM curves – Pearls and Details    • Read KM curves - Pearls and Details   • The PFS Paradox – a hidden scandal of Kaplan Meier curves    • The PFS Paradox - a hidden scandal of KM c...   • How to make KM curves, a practical guide. Feb 20 2024    • Видео   • Logrank test    • Logranktest - click by click in SPSS and b...   • Kaplan Meier Exam    • KM exam - challenge your knowledge in clin...   00:00 - Introduction 02:49 - RECIST V1.1 principles 10:40 - images - measuring tumors 14:08 - workflow condensing information 18:20 - the original RECIST V1.1 table 24:23 - short comings - errors in RECIST V1.1 40:00 - Success of RECIST V1.1 42:26 - kidney cancer 46:46 - HIF 2 alpha 49:20 – RECIST V1.1 primary endpoint trial 53:00 – approval based on RECIST V1.1